What is ThinkCyte?
Founded in 2016, ThinkCyte operates at the intersection of biotechnology, hardware engineering, and artificial intelligence. The company specializes in single-cell technology, providing biomedical professionals with tools that accelerate biological research and the development of novel diagnostics. By leveraging machine learning to analyze complex biological data, ThinkCyte enables high-precision insights that were previously unattainable, positioning itself as a transformative force in the global life science research landscape. Its headquarters in Tokyo serves as a hub for its multidisciplinary R&D efforts, where it continues to refine its proprietary technology stack to meet the evolving needs of the healthcare and pharmaceutical industries.
How much funding has ThinkCyte raised?
ThinkCyte has raised a total of $97.3M across 4 funding rounds:
Series A
$15.3M
Series B
$26M
Private Equity
$24M
Series C
$32M
Series A (2020): $15.3M with participation from Itochu Technology Ventures, Inc, SPARX Group, SBI Group, and Fuyo General Lease
Series B (2021): $26M led by SBI Group, ITOCHU Technology Ventures, Mirai Creation Fund/SPARX Asset Management, Sumitomo Mitsui Trust Investment Co., and Sysmex
Private Equity (2023): $24M supported by Nomura Holdings, Tokyo Century, and Sumitomo Mitsui Trust Bank
Series C (2024): $32M featuring SMBC Venture Capital
Key Investors in ThinkCyte
SMBC Venture Capital
SMBC Venture Capital is a prominent Japanese firm operating within the venture capital and private equity space, providing strategic financial support to high-growth technology enterprises.
Nomura Holdings
Nomura is a leading Asia-based financial services group that offers an integrated global network, providing comprehensive investment banking and asset management solutions to institutional and corporate clients.
Tokyo Century
Tokyo Century is a specialized financial services provider that combines equipment leasing, specialty financing, and international business expertise to foster corporate growth and innovation.
What's next for ThinkCyte?
With the successful closure of its latest funding round, ThinkCyte is well-positioned to scale its operations and accelerate the commercialization of its single-cell analysis platforms. The strategic capital will likely be deployed toward expanding its global footprint, enhancing its machine learning algorithms, and deepening its partnerships within the clinical diagnostics sector. As the company transitions into this next phase of maturity, the focus will remain on bridging the gap between raw biological data and actionable clinical outcomes, ultimately driving long-term value for its stakeholders and the broader biomedical community.
See full ThinkCyte company page
